294 related articles for article (PubMed ID: 20334537)
21. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of daptomycin on experimental methicillin-resistant Staphylococcus aureus keratitis in rabbits.
Mengeloğlu FZ; Küçükbayrak A; Bucak YY; Erdurmuş M; Taş T; Özyalvaçlı G; Bayram R; Bucak Ö; Akdeniz H
J Ocul Pharmacol Ther; 2013 Dec; 29(10):893-9. PubMed ID: 24070366
[TBL] [Abstract][Full Text] [Related]
23. Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery.
Moshirfar M; Mirzaian G; Feiz V; Kang PC
J Cataract Refract Surg; 2006 Mar; 32(3):515-8. PubMed ID: 16631067
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model.
Oguz H; Ozbilge H; Oguz E; Gurkan T
Curr Eye Res; 2005 Mar; 30(3):155-61. PubMed ID: 15804740
[TBL] [Abstract][Full Text] [Related]
25. Comparative efficacy of topical moxifloxacin versus ciprofloxacin and vancomycin in the treatment of P. aeruginosa and ciprofloxacin-resistant MRSA keratitis in rabbits.
Aliprandis E; Ciralsky J; Lai H; Herling I; Katz HR
Cornea; 2005 Mar; 24(2):201-5. PubMed ID: 15725889
[TBL] [Abstract][Full Text] [Related]
26. New therapy option for treatment of methicillin-resistant Staphylococcus aureus keratitis: tigecycline.
Goktas S; Kurtoglu MG; Sakarya Y; Ugurluoglu C; Ozcimen M; Sakarya R; Alpfidan I; Ivacık IS; Erdogan E; Bukus A
J Ocul Pharmacol Ther; 2015 Mar; 31(2):122-7. PubMed ID: 25330310
[TBL] [Abstract][Full Text] [Related]
27. The In Vitro Evaluation of Tigecycline and the In Vivo Evaluation of RPX-978 (0.5% Tigecycline) as an Ocular Antibiotic.
Romanowski EG; Kowalski TA; O'Connor KE; Yates KA; Mah FS; Shanks RM; Kowalski RP
J Ocul Pharmacol Ther; 2016 Mar; 32(2):119-26. PubMed ID: 26545167
[TBL] [Abstract][Full Text] [Related]
28. Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures.
Fintelmann RE; Hoskins EN; Lietman TM; Keenan JD; Gaynor BD; Cevallos V; Acharya NR
Arch Ophthalmol; 2011 Apr; 129(4):399-402. PubMed ID: 21482865
[TBL] [Abstract][Full Text] [Related]
29. Staphylolysin is an effective therapeutic agent for Staphylococcus aureus experimental keratitis.
Barequet IS; Bourla N; Pessach YN; Safrin M; Yankovich D; Ohman DE; Rosner M; Kessler E
Graefes Arch Clin Exp Ophthalmol; 2012 Feb; 250(2):223-9. PubMed ID: 21947265
[TBL] [Abstract][Full Text] [Related]
30. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
Segreti J; Jones RN; Bertino JS
J Ocul Pharmacol Ther; 2012 Feb; 28(1):3-11. PubMed ID: 21999341
[TBL] [Abstract][Full Text] [Related]
31. Comparative efficacy of topical gatifloxacin with ciprofloxacin, amikacin, and clarithromycin in the treatment of experimental Mycobacterium chelonae keratitis.
Hyon JY; Joo MJ; Hose S; Sinha D; Dick JD; O'Brien TP
Arch Ophthalmol; 2004 Aug; 122(8):1166-9. PubMed ID: 15302657
[TBL] [Abstract][Full Text] [Related]
32. Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus.
Blondeau JM; Borsos S; Hesje CK
J Chemother; 2007 Apr; 19(2):146-51. PubMed ID: 17434822
[TBL] [Abstract][Full Text] [Related]
33. In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates.
Harper T; Miller D; Flynn HW
Ophthalmology; 2007 May; 114(5):871-5. PubMed ID: 17383732
[TBL] [Abstract][Full Text] [Related]
34. Zymar (Gatifloxacin 0.3%) shows excellent Gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand White rabbit keratitis model.
Mah FS; Romanowski EG; Kowalski RP; Yates KA; Gordon YJ
Cornea; 2007 Jun; 26(5):585-8. PubMed ID: 17525656
[TBL] [Abstract][Full Text] [Related]
35. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
[TBL] [Abstract][Full Text] [Related]
36. Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis.
Thibodeaux BA; Dajcs JJ; Caballero AR; Marquart ME; Girgis DO; O'Callaghan RJ
Curr Eye Res; 2004 May; 28(5):337-42. PubMed ID: 15287370
[TBL] [Abstract][Full Text] [Related]
37. A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis.
Bu P; Riske PS; Zaya NE; Carey R; Bouchard CS
J Ocul Pharmacol Ther; 2007 Jun; 23(3):213-20. PubMed ID: 17593004
[TBL] [Abstract][Full Text] [Related]
38. Staphylococcus aureus infection of the rabbit cornea following topical administration.
Tang A; Balzli CL; Caballero AR; McCormick CC; Taylor SD; O'Callaghan RJ
Curr Eye Res; 2012 Dec; 37(12):1075-83. PubMed ID: 22916736
[TBL] [Abstract][Full Text] [Related]
39. Effect of propolis in the treatment of experimental Staphylococcus aureus keratitis in rabbits.
Oksuz H; Duran N; Tamer C; Cetin M; Silici S
Ophthalmic Res; 2005; 37(6):328-34. PubMed ID: 16138004
[TBL] [Abstract][Full Text] [Related]
40. Antibiotic effects of WP-0405, a thermo-setting ofloxacin gel, on methicillin-resistant Staphylococcus aureus keratitis in rabbits.
Fukaya Y; Kurita A; Tsuruga H; Naito A; Nakaya S; Sato M; Kamata Y; Hirata H; Kambara Y; Kurasawa N; Wada T; Toyoda Y; Shirasawa E; Ohashi Y
J Ocul Pharmacol Ther; 2006 Aug; 22(4):258-66. PubMed ID: 16910867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
